Hansa Biopharma names Fredrik Röök as VP business development
Swedish rare diseases company Hansa Biopharma (STO: HNSA) today announced that Fredrik Röök has been appointed as vice president business development effective August 17. Mr Röök will report to chief executive Renée Aguiar-Lucander.
Mr Röök brings more than 20 years of experience in business development, licensing, and strategic transactions across the global life science industry. He joins Hansa from AstraZeneca (LSE: AZN), where he served as senior director, global business development, leading complex partnering activities including M&A, in- and out-licensing, divestments, and strategic collaborations. He has a strong track record of executing transactions across all stages, from early innovation to commercial assets, across pharma, biotech, and venture-backed environments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze